203 related articles for article (PubMed ID: 24045180)
1. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
2. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
[TBL] [Abstract][Full Text] [Related]
3. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
Clarke PA; Roe T; Swabey K; Hobbs SM; McAndrew C; Tomlin K; Westwood I; Burke R; van Montfort R; Workman P
Oncogene; 2019 Jun; 38(25):5076-5090. PubMed ID: 30905967
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
5. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
6. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
7. Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.
Weston VJ; Wei W; Stankovic T; Kearns P
Exp Hematol; 2018 Jul; 63():52-63.e5. PubMed ID: 29656114
[TBL] [Abstract][Full Text] [Related]
8. Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.
Melotti L; Meco D; Battaglia A; Buzzonetti A; Martini M; Ruggiero A; Scambia G; Riccardi R
Oncol Rep; 2021 Feb; 45(2):752-763. PubMed ID: 33416182
[TBL] [Abstract][Full Text] [Related]
9. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
11. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway.
Shirakawa J; Tajima K; Okuyama T; Kyohara M; Togashi Y; De Jesus DF; Basile G; Kin T; Shapiro AMJ; Kulkarni RN; Terauchi Y
Diabetologia; 2020 Mar; 63(3):577-587. PubMed ID: 31897526
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
13. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Pitts TM; Tan AC; Kulikowski GN; Tentler JJ; Brown AM; Flanigan SA; Leong S; Coldren CD; Hirsch FR; Varella-Garcia M; Korch C; Eckhardt SG
Clin Cancer Res; 2010 Jun; 16(12):3193-204. PubMed ID: 20530704
[TBL] [Abstract][Full Text] [Related]
14. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
Kan G; Wang Z; Sheng C; Chen G; Yao C; Mao Y; Chen S
Adv Sci (Weinh); 2021 May; 8(10):2004344. PubMed ID: 34026451
[TBL] [Abstract][Full Text] [Related]
15. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
Sale MJ; Cook SJ
Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells.
Tsui J; Qi S; Perrino S; Leibovitch M; Brodt P
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33916323
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.
Jing C; Li H; Du Y; Cao H; Liu S; Wang Z; Ma R; Feng J; Wu J
Mol Med Rep; 2019 Feb; 19(2):1092-1100. PubMed ID: 30535504
[TBL] [Abstract][Full Text] [Related]
19. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
20. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Gong J; Chen Y; Yang L; Pillai R; Shirasawa S; Fakih M
Anticancer Res; 2017 Jun; 37(6):2831-2838. PubMed ID: 28551618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
